MX2015011386A - Metodo para tratar cancer pancreatico. - Google Patents

Metodo para tratar cancer pancreatico.

Info

Publication number
MX2015011386A
MX2015011386A MX2015011386A MX2015011386A MX2015011386A MX 2015011386 A MX2015011386 A MX 2015011386A MX 2015011386 A MX2015011386 A MX 2015011386A MX 2015011386 A MX2015011386 A MX 2015011386A MX 2015011386 A MX2015011386 A MX 2015011386A
Authority
MX
Mexico
Prior art keywords
pancreatic cancer
methods
treating pancreatic
notch
treating
Prior art date
Application number
MX2015011386A
Other languages
English (en)
Spanish (es)
Inventor
Timothy Charles Hoey
Ann M Kapoun
Chun Zhang
Original Assignee
Oncomed Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oncomed Pharm Inc filed Critical Oncomed Pharm Inc
Publication of MX2015011386A publication Critical patent/MX2015011386A/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407Specifically defined cancers
    • G01N33/57438Specifically defined cancers of liver, pancreas or kidney
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/106Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/112Disease subtyping, staging or classification
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/158Expression markers
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705Assays involving receptors, cell surface antigens or cell surface determinants
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/52Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Oncology (AREA)
  • Pathology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Mycology (AREA)
MX2015011386A 2013-03-15 2014-03-13 Metodo para tratar cancer pancreatico. MX2015011386A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361794788P 2013-03-15 2013-03-15
PCT/US2014/026094 WO2014151606A2 (en) 2013-03-15 2014-03-13 Methods of treating pancreatic cancer

Publications (1)

Publication Number Publication Date
MX2015011386A true MX2015011386A (es) 2016-02-03

Family

ID=51581651

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015011386A MX2015011386A (es) 2013-03-15 2014-03-13 Metodo para tratar cancer pancreatico.

Country Status (11)

Country Link
US (1) US20160030561A1 (OSRAM)
EP (1) EP2971146A4 (OSRAM)
JP (1) JP2016520289A (OSRAM)
KR (1) KR20150130466A (OSRAM)
CN (1) CN105051215A (OSRAM)
AU (1) AU2014233736A1 (OSRAM)
CA (1) CA2900969A1 (OSRAM)
HK (1) HK1211322A1 (OSRAM)
IL (1) IL240688A0 (OSRAM)
MX (1) MX2015011386A (OSRAM)
WO (1) WO2014151606A2 (OSRAM)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2032166T3 (pl) 2006-06-13 2013-09-30 Oncomed Pharm Inc Kompozycje i sposoby diagnozowania i leczenia nowotworów
CA2676008A1 (en) 2007-01-24 2008-07-31 Oncomed Pharmaceuticals, Inc. Compositions and methods for diagnosing and treating cancer
US9132189B2 (en) 2008-07-08 2015-09-15 Oncomed Pharmaceuticals, Inc. Notch1 binding agents and methods of use thereof
CN102316897B (zh) 2008-07-08 2014-11-05 昂考梅德药品有限公司 Notch结合剂和拮抗剂及其应用方法
EP2970468B1 (en) 2013-03-13 2021-07-07 Novartis AG Notch2 binding molecules for treating respiratory diseases
MX393482B (es) * 2016-05-09 2025-03-24 Inst Nat Sante Rech Med Metodos para clasificar pacientes con un cancer solido
WO2018169779A1 (en) * 2017-03-17 2018-09-20 ImClone, LLC Combination therapy for pancreatic cancer
MX2019012192A (es) * 2017-04-14 2020-01-21 Genentech Inc Métodos de diagnóstico y terapéuticos para el cáncer.
WO2019203255A1 (ja) * 2018-04-19 2019-10-24 公立大学法人横浜市立大学 再構成癌組織を用いた薬剤評価方法
US20250345419A1 (en) * 2022-05-20 2025-11-13 Mayo Foundation For Medical Education And Research Treating chemoresistant cancers with notch3 inhibitors

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040102390A1 (en) * 2002-11-21 2004-05-27 Isis Pharmaceuticals Inc. Modulation of Notch3 expression
WO2005111072A2 (en) * 2004-04-29 2005-11-24 The Trustees Of Columbia University In The City Of New York Notch-based fusion proteins and uses thereof
WO2009036167A1 (en) * 2007-09-14 2009-03-19 Vanderbilt University Targeting of notch3 receptor function for cancer therapy
CN102316897B (zh) * 2008-07-08 2014-11-05 昂考梅德药品有限公司 Notch结合剂和拮抗剂及其应用方法
EP2389390B1 (en) * 2009-01-26 2020-11-04 Academisch Ziekenhuis Leiden h.o.d.n. LUMC Means and methods for modulating notch3 protein expression and/or the coding region of notch3; compositions and use thereof in the treatment of cadasil
RU2012117619A (ru) * 2009-09-30 2013-11-10 Дженентек, Инк. ЛЕЧЕНИЕ ЗЛОКАЧЕСТВЕННЫХ ОПУХОЛЕЙ, УСТОЙЧИВЫХ К ДЕЙСТВИЮ АНТАГОНИСТА Notch1, С ПОМОЩЬЮ АНТАГОНИСТА Notch3

Also Published As

Publication number Publication date
EP2971146A4 (en) 2016-11-09
CA2900969A1 (en) 2014-09-25
WO2014151606A2 (en) 2014-09-25
US20160030561A1 (en) 2016-02-04
KR20150130466A (ko) 2015-11-23
WO2014151606A3 (en) 2014-11-27
HK1211322A1 (en) 2016-05-20
AU2014233736A1 (en) 2015-08-27
IL240688A0 (en) 2015-10-29
JP2016520289A (ja) 2016-07-14
EP2971146A2 (en) 2016-01-20
CN105051215A (zh) 2015-11-11
WO2014151606A4 (en) 2015-01-29

Similar Documents

Publication Publication Date Title
MX2015011386A (es) Metodo para tratar cancer pancreatico.
ZA202208792B (en) Methods of treating and preventing graft versus host disease
PH12019501197A1 (en) Therapeutically active compounds and their methods of use
PH12016500164B1 (en) Therapeutically active compounds and their methods of use
SG10201810615VA (en) Pd-1 / pd-l1 inhibitors for the treatment of cancer
MX2016002826A (es) Anticuerpos anti-b7-h1 para tratar tumores.
MY199426A (en) Aryl ethers and uses thereof
MX2020011783A (es) Terapia de combinacion que involucra anticuerpos contra claudina 18.2 para tratamiento de cancer.
MX2021001425A (es) Compuestos terapeuticos activos y sus usos.
EA201490814A1 (ru) Лечение злокачественной опухоли ингибиторами tor-киназы
MX2015013177A (es) Combinacion de tratamientod de cancer usando microarns e inhibidores de egfr-tki.
MX2015011899A (es) Metodos para el tratamiento de cáncer y prevención de resistencia a los fármacos para el cáncer.
PH12015500169A1 (en) Prediction of treatment response to jak/stat inhibitor
MX2015012106A (es) Combinacion de un inhibidor de egfr t790m y un inhibidor de egfr para el tratamiento del cancer pulmonar de celulas no pequeñas.
MX2023011187A (es) Metodos para tratar el cancer de prostata.
BR112017012142A2 (pt) método para predição da resposta a agentes terapêuticos para o câncer de mama e método de tratamento de câncer de mama
EA201591987A1 (ru) Лечение злокачественной опухоли дигидропиразинопиразинами
EA201590744A1 (ru) Лечение рака tor киназными ингибиторами
MX2015013021A (es) 5-bromo-indirrubinas.
EA201690445A1 (ru) Лечение рака
EA201690446A1 (ru) Лечение множественной миеломы
MX366911B (es) Método para evaluar y predecir la eficacia del tratamiento del cáncer de mama con un inhibidor de topoisomerasa i de acción prolongada.
NZ631749A (en) Methods of treating cancer using angiogenin or an angiogenin agonist
MX350868B (es) Medicamentos y metodos para tratar cancer.
EA201990411A1 (ru) Способы лечения рака предстательной железы